Mifepristone for Delayed Pregnancy Loss
The purpose of this clinical research study is to learn more about the use of the study drug, CCT-102 (mifepristone and misoprostol), for the potential treatment of early pregnancy loss (i.e. miscarriage management).
Early pregnancy loss is defined as a miscarriage that happens in the first 3 months of pregnancy where the cervix remains closed and there is no bleeding or the bleeding is slight. In this study the study drug will be compared to a standard treatment for early pregnancy loss called expectant management (known as “watchful waiting”). Participants will be randomly assigned to either the study drug regimen or expectant management. We are evaluating how many women complete the miscarriage (pass the pregnancy) by the end of week 1.
Eligibility:
- Between 18-50 years of age
- Have been diagnosed with an early pregnancy loss in the first trimester of pregnancy (an abnormal pregnancy that will miscarry)
- Have had little or no bleeding since diagnosis of early pregnancy loss
Compensation:
Up to $595 for completing the study.
Who to contact for additional information:
To find out more information and to learn if you are qualified to participate, fill out the online form, call the Women's Health Research Unit confidential recruitment line at 503-494-3666 or email us at whru@ohsu.edu.
Complete the following online form: